Memorial Sloane Kettering Cancer Center MSKCC
Welcome,         Profile    Billing    Logout  
 7 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shoushtari, Alexander
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Nasopharyngeal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/24
12/24
NCT01587352: Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Active, not recruiting
2
40
US
Laboratory Biomarker Analysis, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI), Institut Curie Paris, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center P2C
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
12/24
12/24
NCT03420508: Treating Patients With Melanoma and ALK Alterations With Ensartinib

Active, not recruiting
2
18
US
Ensartinib, ALKATI by Customized Nanostring Assay
Memorial Sloan Kettering Cancer Center, Xcovery Holding Company, LLC
Melanoma
01/25
01/25
NCT05384496: Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Recruiting
2
20
US
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Memorial Sloan Kettering Cancer Center, Pfizer
Mucosal Melanoma
05/26
05/26
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Completed
1/2
113
US
Tebentafusp (IMCgp100), durvalumab, MEDI4736, tremelimumab
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
06/23
NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
NCT05415072 / 2021-003380-95: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Recruiting
1/2
124
Europe, US, RoW
DYP688
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Uveal Melanoma
09/25
09/25
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
NCT05607095: Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma

Recruiting
1
10
US
Lifileucel (LN-144)
Memorial Sloan Kettering Cancer Center, Iovance Biotherapeutics, Inc.
Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
05/25
05/25
NCT05640193: A Study of LN-144 in People With Metastatic Melanoma to the Brain

Active, not recruiting
1
10
US
Lifileucel (LN-144)
Memorial Sloan Kettering Cancer Center, Iovance Biotherapeutics, Inc.
Metastatic Melanoma
11/25
11/25
Station, Shirlanna
NCT05415072 / 2021-003380-95: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Recruiting
1/2
124
Europe, US, RoW
DYP688
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Uveal Melanoma
09/25
09/25
Rogers, Caitlin
NCT05415072 / 2021-003380-95: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Recruiting
1/2
124
Europe, US, RoW
DYP688
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Uveal Melanoma
09/25
09/25
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Active, not recruiting
1
120
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30

Download Options